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Deregulated expression of TANK in glioblastomas triggers
pro-tumorigenic ERK1/2 and AKT signaling pathways
J Stellzig1, A Chariot2,3, K Shostak2, S Ismail Go¨ktuna2, F Renner1,6, T Acker4, A Pagenstecher5 and ML Schmitz1
Signal transmission by the noncanonical IkappaB kinases (IKKs), TANK-binding kinase 1 (TBK1) and IKKe, requires interaction with
adapter proteins such as TRAF associated NF-kB activator (TANK). Although increased expression or dysregulation of both kinases
has been described for a variety of human cancers, this study shows that deregulated expression of the TANK protein is frequently
occurring in glioblastomas (GBMs). The functional relevance of TANK was analyzed in a panel of GBM-derived cell lines and revealed
that knockdown of TANK arrests cells in the S-phase and prohibits tumor cell migration. Deregulated TANK expression affects
several signaling pathways controlling cell proliferation and the inﬂammatory response. Interference with stoichiometrically
assembled signaling complexes by overexpression or silencing of TANK prevented constitutive interferon-regulatory factor 3 (IRF3)
phosphorylation. Knockdown of TANK frequently prevents constitutive activation of extracellular signal-regulated kinases 1 and 2
(ERK1/2). TANK-mediated ERK1/2 activation is independent from the canonical MAP kinase or ERK kinase (MEK) 1/2-mediated
pathway and utilizes an alternative pathway that uses a TBK1/IKKe/Akt signaling axis, thus identifying a novel pathway suitable to
block constitutive ERK1/2 activity.
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INTRODUCTION
Glioblastoma multiforme (GBM) is the most common malignant
primary brain tumor, which is characterized by morphological
heterogeneity, as also reﬂected by its original description as
‘glioblastoma multiforme’.1 The histological and molecular
diversity of GBMs creates a state where tumor growth is fueled
by the simultaneous activity of multiple signaling pathways. The
ability of GBMs to diffusely inﬁltrate throughout the brain tissue
and its resistance to chemotherapy restricts median survival to
only 14 months. Extensive proﬁling of GBM genomes and their
epigenetic status has allowed the identiﬁcation of at least four
subtypes of GBM: classical, mesenchymal, proneural and neural.2,3
Although each subtype is characterized by speciﬁc groups of
frequently occurring mutations and deregulated signaling
pathways, further mutations stereotypically occur in all GBM
subgroups. These include mutations in epidermal growth factor
receptor and further receptor tyrosine kinase pathways.4
Various mutations activate few oncogenic pathways that closely
interact to produce an oncogenic signaling network that is
instrumental in the expression and maintenance of a malignant
phenotype. Aberrant activation of the MAP kinase or ERK kinase
(MEK) 1/2 and extracellular signal-regulated kinases 1 and 2 (ERK1/
2) occurs in many types of human cancers.5 Sustained ERK
signaling is a requirement for S-phase entry and allows
proliferation of tumor cells.6 GBMs often show constitutive
activation of the pro-survival kinase AKT.7 The full activity of this
kinase depends on Phosphoinositide-dependent protein kinase
1-mediated phosphorylation of T308 in the activation loop and
mammalian target of rapamycin-triggered phosphorylation of S473
in the hydrophobic domain. These phosphorylations can be either
triggered in a phosphatidylinositol 3 kinase-dependent manner or
alternatively both sites can be directly phosphorylated by the
noncanonical IkappaB kinases (IKKs), TANK-binding kinase 1 (TBK1)
or IKKe.8–10 IKKe is also called inducible IkB kinase, as its mRNA
expression can be augmented by lipopolysaccharide. IKKe and
TBK1 are related to the canonical IKKs,11 which are key
components of the classical nuclear factor-kB (NF-kB) activation
pathway. Although the proinﬂammatory functions of IKKe and
TBK1 in immune signaling rely on their ability to phosphorylate
interferon-regulatory factor (IRF) 3 and 7 and NF-kB subunits,
genetic studies have revealed that deregulated noncanonical IKKs
are causative for metabolic diseases, oncogenesis and
chemoresistance.12,13 Point mutations are only rarely detected,
but overexpression is frequently found in a variety of cancers
including gliomas.14 Overexpression of IKKe is observed in ovarian
and pancreatic cancer and most strikingly in one third of breast
cancers where it has transforming activity. TBK1 has been linked to
Ras-induced oncogenic transformation where activation of Ral-GEF
leads to the formation of the exocyst complex consisting of TBK1,
RalB and Sec5.15 Constitutive TBK1 activation supports oncogenic
transformation and suppresses oncogene-induced apoptosis.16,17
Both noncanonical IKKs are found in association with at least four
adapter proteins called TRAF associated NF-kB activator (TANK),
SINTBAD, optineurin and NAP1. Detailed biochemical studies
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showed mutual exclusive interaction of the adapters with their
kinases, thus revealing the existence of distinct alternative protein
complexes.18,19 All four adapters compete for binding to a
C-terminal coiled-coil region of TBK1, an interaction that is
required for TBK1 function.20,21
Adapter proteins typically lack intrinsic enzymatic activities,
but act as platforms to assemble functional complexes.22
Therefore, adapter proteins coordinate signal speciﬁcity, aid
to deﬁne the quality of the signal output and allow crosstalk
with other signaling pathways. Accordingly, TANK is required
to allow a physical and functional crosstalk between non-
canonical and classical IKK complexes.23,24 TANK does not
function as a general regulator of NF-kB signaling and rather
functions to restrict Toll-like receptor 7-triggered activation of
NF-kB and AP1.25,26
Here we show that GBMs frequently display extremely variable
expression levels of the TANK protein. Knockdown experiments
allowed the discovery of novel pro-proliferative signaling path-
ways, as TANK depletion frequently prohibited constitutive
phosphorylation of ERK1/2, AKT and IRF3. Loss of TANK expression
impaired S-phase progression and cell migration, thus revealing
that also dysregulation of adapter proteins can affect tumorigenic
signaling networks.
RESULTS
Dysregulated TANK expression in GBMs
Given the elevated expression of IKKe in a variety of cancers
including gliomas13,27 and the involvement of TBK1 in onco-
genesis, it was then interesting to investigate potential expression
changes of the associated adapter protein TANK. To address this
question, we performed an in silico expression analysis by
comparing different microarray studies of various normal and
tumor tissues from the Oncomine integrated cancer database
(http://www.oncomine.org). The data sets revealed a strongly
increased expression of TANK mRNAs in GBMs (Figures 1a and b).
To investigate whether increased TANK levels are also seen at the
protein level, western blotting experiments with samples from
excised GBMs (WHO grade IV) and anaplastic astrocytomas (WHO
grade III) were performed. These studies uncovered highly variable
expression levels of TANK and also of the associated kinases TBK1
and IKKe (Figure 1c). In line with published literature,28,29 also
phosphorylation and thus activation of kinases allowing survival
(AKT) and proliferation (ERK1/2) of tumor cells was frequently
elevated in the gliomas (Figure 1c). The quantitative analysis of
transcripts from the samples where RNA was also available
showed that the highly dynamic range of protein expression levels
is reﬂected at the mRNA level (Figures 1d and e). As the excised
GBM material contains heterogeneous cell populations and also
some nontransformed cells surrounding the tumor, it was then
interesting to compare TANK expression levels in GBM cell lines.
As each tumor cell line has speciﬁc defects in individual signaling
networks, we analyzed a battery of different GBM and astrocytoma
cell lines in order to get a more general picture. Protein expression
levels of TANK showed a great variability with the relatively lowest
levels in T98G cells and much less variability for IKKe and TBK1
(Figure 2a). Most cell lines also showed constitutive phosphoryla-
tion of AKT and ERK1/2 kinases. The analysis of mRNA expression
revealed highly variable and elevated expression levels of TANK in
6 of the 11 analyzed cell lines (Figure 2b). Increased mRNA
expression was restricted to TANK and not observed for TBK1/IKKe
(Figure 2c). This might be due to the lack of tumor-associated cell
populations creating a proinﬂammatory microenvironment that in
turn could cause an elevated transcription of the kinases in cell
lines. To investigate the mechanisms responsible for differential
TANK expression, we compared cell lines characterized by
high (A764) or low (U251 and U87MG) TANK transcript levels.
De novo synthesis of TANK mRNA was measured using an indirect
approach, as occupation of the TANK gene by active RNA
polymerase II (marked by phosphorylation at S2) was used as an
indicator of ongoing transcription. Chromatin immunoprecipita-
tion experiments showed the increased occurrence of active RNA
Pol II at the Tank gene in A764 cells (Figure 2d), thus revealing
clear differences in ongoing transcription. To compare the mRNA
stabilities between the cell lines, cells were treated for various
periods with the transcription inhibitor actinomycin D, followed by
determination of mRNA levels by quantitative PCR. These
experiments showed signiﬁcant variations in TANK mRNA
stabilities, but largely unchanged levels of TBK1 transcripts
(Figure 2e).
Knockdown experiments were performed to test the functional
relevance of TANK and its associated kinase TBK1 for proliferation
of GBM cells. As exempliﬁed for A172 cells, the proliferation of four
cell lines was completely dependent on the expression of both
proteins (Figure 3a). Of note, the knockdown of TANK also
downregulated TBK1 and vice versa, reinforcing the notion that
TBK1 and TANK stabilize each other to promote cell proliferation.
Further four cell lines (as exempliﬁed by SNB19 cells) did not grow
after knockdown of TANK, whereas depletion of TBK1 only slightly
retarded cell proliferation (Figure 3b). TANK knockdown had only
moderate or even no inhibiting effect on the proliferation of
Ln229 (Figure 3c) and T98G cells, respectively. These experiments
are summarized in Figure 3d and collectively show a complete or
at least partial dependence on TANK expression in 10 out of 11
cell lines. TBK1 critically drives cell proliferation in nine cell lines.
However, its contribution could not be assessed in both T98G and
U118 cells, as we failed to signiﬁcantly deplete TBK1 in those cells
(data not shown).
TANK is required for S-phase transition and cell migration
As TANK knockdown did not result in apoptosis (data not shown),
it was then interesting to determine its impact on the cell cycle. In
some cell lines, downregulation of TANK caused accumulation in
S-phase, whereas other cell lines such as A764 cells did not show
any TANK or TBK1-dependent changes of cell cycle phases
(Figure 4a). To monitor the dynamic distribution of the cell cycle
phases in A764 cells, control and knockdown cells were arrested at
late G2 by treatment with vinblastine. One day after the addition
of vinblastine, most of the control cells had accumulated at G2,
whereas cells depleted for TANK or TBK1 remained almost entirely
in the G1 or S-phase (Figure 4b), indicating that they cannot
further progress throughout the cell cycle. As GBMs are
characterized by their ability to migrate and diffusely inﬁltrate
throughout the brain tissue,4 we then tested a possible
contribution of TANK for cell migration. Scratch assays showed
an almost complete closure of the gap after 24 h in control cells,
whereas the downregulation of TANK strongly decreased the
migration of GBM cells, as exempliﬁed for U251 (Figure 4c) and
U373 (Figure 4d) cells. In each case, the migration-restricting
ability of TBK1 was less pronounced. Of note, depletion of TANK
did not always result in inhibition of migration, as exempliﬁed for
T98G cells, which migrate even in the absence of TANK
(Supplementary Figure S1).
TANK and TBK1 expression promotes phosphorylation of
Akt and ERK
To further understand how TBK1 and TANK promote cell
proliferation and migration at the molecular level in GBM-derived
cells, cells were depleted for each of these proteins and then
analyzed for the activity status of AKT and ERK1/2 with phospho-
speciﬁc antibodies. Knockdown of TBK1 impaired the consti-
tutive AKT phosphorylation at T308 and S473 in ﬁve cell lines
(A172, A271, A746, Ln229 and U343; Figures 5a and b and
Supplementary Figure S2), showing its important contribution
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that cannot be compensated by Phosphoinositide-dependent
protein kinase 1-derived or mammalian target of rapamycin-
derived phosphorylations. Interestingly, TBK1 knockdown resulted
in a slight and partial impairment of constitutive ERK1/2
phosphorylations in four cell lines (A271, Ln229, SNB19 and
U251). Downregulation of TANK impaired AKT phosphorylation
only in U373 and U251 cells, whereas it strongly precluded ERK1/2
phosphorylation in six cell lines (A172, A271, Ln229, SNB19, U251
and U373; Figures 5c and d and Supplementary Figure S3).
To investigate the signaling networks delivering TANK-derived
signals to ERK1/2 in TANK addicted cells, phosphorylations
were monitored after inhibition of speciﬁc kinases. ERK1/2
phosphorylation can be mediated either by the upstream kinases
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Figure 1. Deregulated expression of members of the noncanonical IKK complex in GBMs. (a) Analysis of TANK expression in normal brain (light
blue) and GBMs (dark blue). Each bar represents an individual tissue sample (Reporter ID: 209451_at; Nucleotide Acc. No.: U59863). (b) Box
plots of data from the Oncomine data sets comparing healthy brains and GBMs plotted on a log scale. Median values are shown by horizontal
bars, the upper part of the box shows 75th percentile and the lower part the 25th percentile. The upper part of the bar shows 90th percentile
and the lower part the 10th percentile. The points show outlier values, the figure was created using the Oncomine 3.0 software.
(c) Comparable amounts of total proteins extracted from GBMs, astrocytomas and healthy brain were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, sample numbers are shown at the top. After blotting to a membrane, the samples were analyzed by
immunoblotting for the occurrence and phosphorylation state of the indicated proteins with specific antibodies. The antibodies detecting
b-actin were used to ensure comparable protein loading. As the samples could not be analyzed on one gel, the displayed exposure times were
chosen to allow direct comparison between the samples. (d) RNA was extracted from the indicated samples where available. After preparation
of complementary DNA, the relative expression amounts of TANK, IKKe and TBK1 were determined by quantitative PCR (qPCR) using specific
primers. Expression in normal brain (NB) was arbitrarily set as 1, error bars show standard deviations from two experiments performed in
triplicate. (e) Box plot analysis of the data shown in (d). Horizontal bars show median values, vertical bars show the standard deviations and
the points show outlier values.
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relative contribution of these two pathways, cells were grown in
the presence of the MEK1/2 inhibitor U0126 or the Akt inhibitor
VIII. The analysis of ERK1/2 phosphorylation showed that the vast
majority of GBM cell lines rely on AKT-delivered signals (Figure 6a).
Of note, inhibition of MEK1/2 often resulted in exaggerated AKT
phosphorylation, indicating the possible existence of a negative
feedback loop. Inhibition of the TANK-associated kinases TBK1/
IKKe with BX795 resulted in absent phosphorylation of AKT and
ERK1/2 in the majority of cell lines, showing that these kinases
lead to AKT-dependent ERK1/2 activation (Figure 6b). Inhibition
of TAK1, a kinase with a central role for NF-kB signaling,32
remained without impact on ERK1/2 but resulted in enhanced
AKT phosphorylation (Figure 6c), probably due to another
negative feedback loop. Major efforts have been undertaken
to inhibit constitutive activity of ERK1/2 in cancer,33 but cancer
cells are frequently resistant to MEK1/2 inhibitors.34,35 As we
identiﬁed a novel TANK-AKT signaling pathway leading to ERK1/2
activation, we tested whether the combined inhibition of
MEK1/2 and TBK1/IKKe-derived signals could efﬁciently turn off
ERK1/2 activation. As shown in Figure 6d, treatment with BX795
partially inhibited ERK1/2 activities, whereas the combination of
BX795 with U0126 resulted in a complete blockage of ERK1/2
phosphorylation.
GBMs are frequently treated with the chemotherapeutic agents
temozolomide or cytarabine. To investigate whether the thera-
peutic efﬁcacy of these drugs can improve upon concomitant
TBK1/IKKe inhibitions, temozolomide was administered either
alone or in combination with BX795 to GBM cell lines.
Temozolomide-induced cell death was enhanced upon simulta-
neous inhibition of TBK1/IKKe signaling, but beneﬁcial effects were
only moderate (Figure 6e) or even absent when BX795 and
cytarabine treatments were combined (Supplementary Figure S4).
These ﬁndings are consistent with the concept that chemother-
apeutic drugs only affect rapidly proliferating cells and not cells
that are slowed down in their proliferation upon interference with
noncanonical IKK signaling.
TANK regulates inﬂammatory signaling cascades
As TANK physiologically dampens inﬂammatory signaling upon
interference with TRAF6 activation,25 it was then interesting to
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Figure 2. Deregulated expression of members of the noncanonical IKK complex in glioma cell lines. (a) Equal amounts of proteins extracted
from the indicated cell lines were analyzed by immunoblotting for expression and phosphorylation of the indicated proteins. Exposure times
were chosen in a way that allows comparison between cell lines in the dynamic range of the film. (b) Comparative analysis of mRNAs
encoding TANK, IKKe and TBK1. The mRNA levels were quantified in the indicated cell lines by quantitative PCR (qPCR). Expression levels in
T98G cells were arbitrarily set as 1, error bars are derived from two experiments performed in triplicates. (c) Box plot analysis of the data
shown in (b). Vertical bars show the standard deviations, horizontal bars show median values and the points show outlier values. (d) Proteins
were crosslinked to the DNA with formaldehyde in the indicated cell lines and chromatin immunoprecipitation (ChIP) assays were performed
using a Pol II phospho S2 antibody or an unspecific IgG control antibody. Binding of Pol II S2p to the Gapdh control and two regions (#1 and
#2) in the Tank gene were quantified by qPCR. To allow a direct comparison between the cell lines, data were normalized for binding
of phosphorylated Pol II to the Gapdh gene. Maximal binding of phosphorylated Pol II was arbitrarily set as 100%, standard deviations are
shown. (e) The different cells were treated with actinomycin D (1 mg/ml) for the indicated periods, followed by RNA isolation, complementary
DNA production and the analysis of expression levels by qPCR. Error bars show standard deviations from two experiments performed
in triplicates.
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signaling. Knockdown of TANK in U373 cells resulted in strongly
impaired constitutive phosphorylation of IRF3 (Figure 7a), a
transcription factor that may interfere with glioma proliferation,
migration and invasion.36 Consistent with the concept that
overexpression of adapter proteins interferes with signaling by
preventing stoichiometric assembly of multi-protein signaling
complexes,37 also overexpression of TANK resulted in the
inhibition of IRF3 phosphorylation (Figure 7b). Accordingly,
TBK1- or IKKe-triggered transcription of a luciferase reporter gene
controlled by the interferon b promoter was impaired after TANK
expression in a dose-dependent manner (Figure 7c). At the level of
gene expression, downregulation of TANK resulted in elevated
expression of the proinﬂammatory Tnf and Vcam genes, as
revealed by quantitative PCR (Figures 7d and e). In contrast,
knockdown of TBK1 remained without a major impact on the
expression of these genes in unstimulated cells. These results
suggest that deregulated TANK expression in tumors has not only
consequences for cell proliferation but also on the signaling
network mediating proinﬂammatory gene expression.
DISCUSSION
Mechanisms of deregulated TANK expression in GBMs
Here we show that TANK overexpression and deregulated
expression of noncanonical IKKs are frequently found in GBMs.
The molecular mechanisms leading to elevated TANK expression
remain unknown. Increased mRNA expression of the Tank
gene may be due to overexpression of its positive regulator
Sox11, a transcription factor that is frequently found to be
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Figure 3. Many GBM cell lines are addicted to TANK. (a) A172 cells were retrovirally transduced to express short hairpin RNAs (shRNAs) leading
to a knockdown of TANK, TBK1 or a scrambled shRNA as a control. Transduced cells were selected with puromycin and used to determine cell
proliferation (upper) or alternatively protein expression and cell viability (lower). Proliferation was measured by plating out equal numbers of
cells, followed by determination of cell numbers after 3 and 5 days using a FACSCalibur. Error bars show standard deviations from three
different experiments. Aliquots of the cells were lysed and tested by western blotting for efficient knockdown. Equal numbers of cells were
also seeded and used 2 days later for MTT assays, which reflect the metabolic activities and cell proliferation rates. Relative metabolic activity
of control cells was arbitrarily set as 1, error bars show standard deviations. (b and c) The experiment was done as in (a) but it shows the
experiment for cells, which are representative for groups that are only partially addicted from TBK1 (b) or TBK1 and TANK (c). (d) Summary of
the cell proliferation assays. þ þ shows completely absent and þ shows impaired proliferation after knockdown. ND indicates not
determinable, as TBK1 knockdown in T98G and U118 cells turned out not to be efficient.
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Figure 4. TANK can regulate the S-phase progression and contributes to cell migration. (a) The indicated cell lines were used to knockdown
TANK or TBK1. After selection with puromycin, cells were used for quantitative analysis of cycle phases using a FACSCalibur (upper) and also
for western blotting to ensure efficient knockdown (lower). (b) A764 cells were transduced to knock down expression of TANK or TBK1 as
shown and then treated for the indicated periods with vinblastine. The cell cycle phases of propidium iodide stained cells were determined by
fluorescence-activated cell sorting (FACS) as shown. (c) The indicated knockdown and control U251 cells were grown to density and treated
with the DNA polymerase inhibitor aphidicolin (1mg/ml) to prevent proliferation. After scratching of the cell monolayer migration of cells was
examined using a NIKON Eclipse TE2000-E life cell imaging microscope (Nikon, Du¨sseldorf, Germany). The right part shows a quantitative
analysis of cell migration, error bars were derived from two independent experiments performed in triplicates. (d) The experiment was done
as in (c) with the exception that U373 cells were analyzed.
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by gene array or RNA-seq experiments do not always correlate
with protein expression levels, as exempliﬁed by the U87MG cell
line. Here, the relatively moderate mRNA expression levels
are contrasted by robust expression of the TANK protein. As
protein expression levels can be regulated by multiple
mechanisms that include checkpoints controlling mRNA
processing and stability, translation initiation as well as protein
stability,39 mRNA levels are not necessarily reﬂecting protein
abundance. As immune-regulating proteins controlling IRF and
NF-kB signaling are frequently found to be regulated at each
stage of gene expression,40 we rather speculate that elevated
TANK expression is due to multiple mechanisms that affect
mRNA synthesis and stability. Our data indicate differential
stabilities of TANK mRNAs (Figure 2e) and accordingly the analysis
of TANK mRNA revealed the occurrence of several distinct
AU-rich elements that could potentially allow docking of
RNA-binding proteins and regulation of mRNA stabilities
(Supplementary Figure S5). Furthermore, a previous study
described a speciﬁc recurrent chromosomal break region at the
chromosome 2q24–2q32 region encompassing the TANK-encod-
ing locus,41 extensive characterizations of GBM genomes failed to
identify frequent gene rearrangements in the TANK-containing
region.42 GBMs often show hypoxic areas with low availability
of oxygen,43 raising the possibility that this could contribute
to the regulation of TANK abundance. However, we failed to
detect major changes in the mRNA and protein expression of
TANK and noncanonical IKKs in hypoxic cells (Supplementary
Figures S6A and B).
TANK-regulated signaling pathways
Only optimal amounts of adapter proteins ensure correct signal
output, as underexpression as well as overexpression cause faulty
signal output, as schematically shown in Figure 7f. In that sense,
the overexpressed TANK protein could compete with SINTBAD,
NAP1 and optineurin for the association with the other 430
regulatory proteins that are known to interact with these
adapters.18 This in turn can affect multiple signaling pathways
simultaneously and thus cause a re-wiring and re-programming of
signaling networks. Obvious candidate enzymes affected by
deregulated TANK expression are the associated kinases TBK1
and IKKe and accordingly overexpression of IKKe has been
associated with impaired apoptosis of glioma cells.27
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Figure 5. Identification of signaling pathways regulated by the noncanonical IKK complex. (a) The indicated cell lines were used to knock
down TBK1 and subsequently analyzed for protein expression and phosphorylation with the indicated antibodies. (b) The TBK1-dependent
coregulation between AKT S473 and T308 phosphorylation is schematically displayed, downward arrows show inhibition of phosphorylation.
(c) The experiment was done as in (a) with the exception that TANK was knocked down. (d) Schematic display of absent coregulation between
AKT and ERK1/2 phosphorylation after downregulation of TANK.
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Figure 6. Noncanonical IKKs activate ERK1/2 via AKT. (a) The indicated cell lines were incubated overnight with the AKT inhibitor VIII (5mM) or
with the MEK1/2 inhibitor U0126 (5 mM), followed by analysis of AKT phosphorylation at T308 or S473 and ERK1/2 phosphorylation by
immunoblotting. The results are schematically displayed, the inhibited enzymes are shown in red, the necessity of enzyme activity (as revealed
by significantly impaired or absent phosphorylation) is shown by arrows representing the different cell lines. Inhibitory kinase activities (as
revealed by exaggerated phosphorylations in the presence of kinase inhibitors) are shown by lines lacking an arrow head. (b) Impact of
BX795-mediated TBK1/IKKe inhibition and (c) 7-oxozeaenol-mediated TAK1 inhibition on the signaling networks. The original blots for the
data sets schematically summarized in (a–c) are shown in Supplementary Figure S8. (d) Ln229 cells were incubated with BX795 (1 mM) and
U0126 (5 mM) at the indicated combinations and phosphorylation of ERK1/2 was analyzed by immunoblotting. (e) The indicated GBM cell lines
were incubated for 72 h with BX795 (1 mM), temozolomide (TMZ; 100 mM) or a combination of both. Cell viability was determined by MTT assays,
error bars show standard deviations from two experiments performed in triplicate.
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coregulated with TANK in brain tumors identiﬁed STAM2 (signal
transducing adaptor molecule) as the top ranking hit
(Supplementary Figure S7), a protein that is also known to
function as an adapter protein.44 Besides the described effects of
IKKe on cell survival, the noncanonical IKKs also mediate ERK1/2
activation, as concluded from the inhibitory activity of BX795 on
constitutive ERK1/2 activity. The results from knockdown
experiments and inhibitor studies suggest that TANK-derived
signals travel via TBK1/IKKe to AKT, which then in turn allows
ERK1/2 activation. It is currently unclear whether TBK1/IKKe
directly activates ERK1/2, or whether it uses AKT as a connecting
kinase. AKT-mediated ERK1/2 activation may rely on its reported
ability to inhibit c-Jun N-terminal kinase, which in turn alleviates the
repressive function of c-Jun N-terminal kinase on ERK1/2 signaling.31
As many tumor cells have learned to induce ERK1/2
phosphorylation by a MEK1/2-independent signaling route,35
the detailed characterization of the molecular mechanisms
allowing for this bypass will be highly relevant. TANK-derived
signals may not only travel via TBK1/IKKe, as ERK1/2
phosphorylation in A271 and U373 cells is affected by
downregulation of TANK but not by BX795. This ﬁnding could be
explained by an inﬂuence of TANK on other signaling molecules.
One candidate is TRAF6 as a previous study showed the inhibitory
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Figure 7. Functional consequences of deregulated TANK expression. (a) TANK or TBK1 were knocked down in U373 cells with specific short
hairpin RNAs (shRNAs), followed by the analysis of NF-kB p65 and IRF3 phosphorylation with specific antibodies. (b) TANK was overexpressed
in U373 cells and extracts were analyzed for NF-kB p65 and IRF3 phosphorylation by western blotting. (c) HEK293 cells were transfected with a
plasmid encoding the luciferase gene under the control of the interferon b (IFNb) promoter along with the indicated expression vectors. After
36 h, cells were lysed and one aliquot was used for the determination of luciferase activity (upper) and the other aliquot was used to
determine adequate protein expression. Error bars were derived from two experiments performed in triplicate. (d and e) TANK or TBK1 were
knocked down in U373 (d) or U251 (e) cells, followed by quantitative analysis of proinflammatory gene expression by quantitative PCR (qPCR).
(f ) Schematic model illustrating that the fidelity of signal output is critically determined by the amount of TANK and the stoichiometric
assembly of functional signaling complexes.
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transducing enzymes contained in the TANK/TBK1 molecular
network may be responsible for these effects.18
This study also shows an effect of TANK on constitutive STAT3
phosphorylation, a transcription factor that mediates upregulation
of interleukin-6 (IL-6), which in turn facilitates glioma development
by promoting angiogenesis and cell proliferation.45 The impact of
TANK on this signaling pathway may well be indirect, as TANK is
known to contribute to a primary IFN response,46 which then
triggers a secondary response involving STAT3 phosphorylation.47
However, TANK could also be involved in an alternatively STAT3
activating pathway downstream from the tyrosine kinase BMX.48
TANK also binds to NF-kB essential modulator, which is the
adapter protein for the canonical NF-kB activating kinases IKKa and
IKKb.24 This interaction allows a crosstalk between TANK and
classical NF-kB activity23 and thus different TANK levels may well
affect the thresholds and kinetics of NF-kB signaling in GBMs. The
functional role of NF-kB activation in GBMs is not yet clear and its
aberrant activation may not be a cause but rather a consequence of
the tumor microenvironment that is characterized by NF-kB
activating conditions such as dysregulated cytokine expression
and hypoxia.49
Inﬂammation in GBM
The signaling pathways discussed above will lead to altered
secretion of cytokines or growth regulatory factors, which then act
in a paracrine or juxtacrine manner to inﬂuence cell proliferation.
The role of inﬂammatory processes for the proliferation of GBMs
does not lead to a coherent picture. Experiments with tumor cell
lines show p38 mitogen-activated protein kinase-dependent
expression of cytokines such as IL-1b, IL-6 and IL-8, which in turn
trigger invasiveness of U251 GBM cells.50 Complex cytokine
networks also mediate the interaction between tumor cells and
untransformed cells in the GBM microenvironment, thus rendering
tumor heterogeneity as an active process.51 On the other hand,
cytokine expression levels occurring in tumor cells or normal brain
cells do not correlate with histopathological parameters such as
necrosis or ischemic necrosis.52 GBMs are also well known for
cancer-associated immune inhibition by soluble factors such as
transforming growth factor-b.53 Accordingly, immunosuppressive
factors secreted by gliomas frequently result in a broad
suppression of cell-mediated immunity.54
In summary, our results show that the deregulated expression
of non-enzymatic adapter proteins such as TANK can have a
profound inﬂuence on signal output from several signaling
networks. Although adapter proteins are not druggable, inter-
ference with adapter-associated enzymes such as TBK1/IKKe can
be useful to restrict aberrant bypassing of signaling pathways in
tumor cells.
MATERIALS AND METHODS
Antibodies, plasmids and reagents
This information is given in the Supplementary Table S1.
Chromatin immunoprecipitation
Proteins and DNA were crosslinked by incubation for 10min with 1% (v/v)
formaldehyde at room temperature, followed by quenching of formalde-
hyde with 0.125 M glycine for 2min and lysis in RIPA buffer as described.55 A
Branson soniﬁer 250 (Emerson, Danbury, CT, USA) was used to shear the
genomic DNA and cellular debris was removed by centrifugation. RNAs
were digested by incubation with RNase A, equal amounts of DNA were
incubated with 2mg of antibodies previously bound to protein G-coupled
Dynabeads. After extensive washing, the precipitated DNA fragments were
eluted. The sequences of the TANK-speciﬁc primers used for chromatin
immunoprecipitation experiments are given in the supplementary section.
The PCR product was quantiﬁed by real-time quantitative PCR with speciﬁc
primers using the Applied Biosystems (Life Technologies, Carlsbad, CA, USA)
7300 real-time PCR system.
Cell lines
HEK293 cells, 293T Phoenix Ampho packaging cells and all GBM cell lines
(A172, A271, A764, G55, Ln229, SNB19, T98G, U118, U251 and U343) and
astrocytoma lines (U373 and U87MG) were grown in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10 % (v/v) fetal calf serum, 2mM
L-glutamine and 1 % (v/v) penicillin/streptomycin.
Cell proliferation and MTT assays
Cells were trypsinized and counted by ﬂuorescence-activated cell sorting
analysis. Constant numbers of cells were plated on 6 cm dishes and further
grown for 72 and 120 h. At these time points, cells were harvested by
trypsinization and cell numbers were determined by ﬂuorescence-
activated cell sorting. Cell viability was quantiﬁed using the Vybrant MTT
Cell Proliferation Assay Kit (Life Technologies, Carlsbad, CA, USA). Cells
were seeded in a 96-well-plate at a density of 1 104 cells per well. After
24 h, the cells were subjected to the indicated treatments and 1 day later
cell viability was measured by adding 10ml of the MTT stock solution
(12mM) to each well, followed by incubation at 37 1C for 4 h. To solubilize
the formazan crystals formed, 100ml of sodium dodecyl sulfate–HCl
solution were added and the plate was incubated at 37 1C for 4–18 h in a
humidiﬁed chamber. The viability was determined by measuring the
absorbance at 570 nm.
Production of retroviruses and lentiviruses
293T Phoenix Ampho packaging cells capable of producing gag-pol and
envelope protein for amphotropic viruses were transfected with either
pSIREN-Scramble, pSIREN-shTANK or pSIREN-shTBK1 vectors using Rotifect
(Roth, Karlsruhe, Germany) according to the manufacturer’s instructions.
Two days after transfection of the virus-producing cells, the virus-
containing supernatant was collected and ﬁltered through a 0.45 mm ﬁlter.
After adding polybrene to a ﬁnal concentration of 5 mg/ml, the supernatant
was added to the GBM cell lines for 24 h. Medium was subsequently
changed back to culture medium. Three days post infection, GBM cell lines
were treated with 2 mg/ml puromycin for at least 5 days to select short
hairpin RNA-expressing cells. All key experiments were repeated with a
second independent short hairpin RNA to exclude off-target effects. TANK
was overexpressed using a lentiviral vector. Viruses were produced in
HEK293T cells by transfecting a lentiviral TANK expression vector together
with the packaging vectors pMDLg/pRRE, pRSV-Rev and pHCMVG using
lipofectamine according to the manufacturer’s instructions. Two days after
transfection, the virus-containing supernatant was collected and used for
infection of GBM cell lines.
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